Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system

It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., ). Since then, metastatic spread of cancer cells to region...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular oncology 2017-07, Vol.11 (7), p.781-791
Hauptverfasser: Karlsson, Mikael C., Gonzalez, Santiago F., Welin, Josefin, Fuxe, Jonas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 791
container_issue 7
container_start_page 781
container_title Molecular oncology
container_volume 11
creator Karlsson, Mikael C.
Gonzalez, Santiago F.
Welin, Josefin
Fuxe, Jonas
description It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., ). Since then, metastatic spread of cancer cells to regional lymph nodes has been established as the most important prognostic factor in many types of cancer (Carter et al., ; Elston and Ellis, ). However, despite its clinical importance, lymph metastasis remains an underexplored area of tumor biology. Fundamental questions, such as when, how, and perhaps most importantly, why tumor cells disseminate through the lymphatic system, remain largely unanswered. Accordingly, no treatment strategies exist that specifically target lymph metastasis. The identification of epithelial‐mesenchymal transition (EMT) as a mechanism, which allows cancer cells to dedifferentiate and acquire enhanced migratory and invasive properties, has been a game changer in cancer research. Conceptually, EMT provides an explanation for why epithelial cancers with poor differentiation status are generally more aggressive and prone to metastasize than more differentiated cancers. Inflammatory cytokines, such as TGF‐β, which are produced and secreted by tumor‐infiltrating immune cells, are potent inducers of EMT. Thus, reactivation of EMT also links cancer‐related inflammation to invasive and metastatic disease. Recently, we found that breast cancer cells undergoing TGF‐β‐induced EMT acquire properties of immune cells allowing them to disseminate in a targeted fashion through the lymphatic system similar to activated dendritic cells during inflammation. Here, we review our current understanding of the mechanisms by which cancer cells spread through the lymphatic system and the links to inflammation and the immune system. We also emphasize how imaging techniques have the potential to further expand our knowledge of the mechanisms of lymph metastasis, and how lymph nodes serve as an interface between cancer and the immune system. This article presents a review on the role of EMT in cancer metastasis through the lymphatic system. The emphasis is on the role of TGF‐beta‐induced EMT as a link between cancer and inflammation, and how EMT cells acquire properties of immune cells.
doi_str_mv 10.1002/1878-0261.12092
format Article
fullrecord <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_496289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A731950653</galeid><sourcerecordid>A731950653</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6392-411f0953a83dc68d61faf30145467829afe5fbd699dc5699143753a29b932e263</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEoqVw5oYiceGSrf8kTuaCVFUtIC3qhZ4trzPZuCT2EidUe-MReMY-CbNkWXURErIlj8a_-ewZfUnymrMFZ0yc86qsMiYUX3DBQDxJTg-ZpxQXZZ6VFfCT5EWMd4wVChQ8T05EVQBjUpwmt1cbN7bYOdM9_PjZY0Rv221vunQcjI9udMGnzqfWeItD2uNoIm0X07EdwrRu6cS02_ab1ozOpnEbR-xfJs8a00V8tT_Pktvrqy-XH7PlzYdPlxfLzCoJIss5bxgU0lSytqqqFW9MIxnPi1yVlQDTYNGsagVQW_o68FyWRAtYgRQolDxLslk33uNmWunN4HozbHUwTu9TXylCnYMSFRD_fubppsfaoqcuu6Oy4xvvWr0O33VBArRJ4N1eYAjfJoyj7l202HXGY5ii5sCAK6WqitC3f6F3YRo8jUMLAUyUXMIjam061M43gd61O1F9UUoOBVOFJGrxD4pWjb2zwWPjKH9UcD4X2CHEOGBz6JEzvXOO3vlE73yifzuHKt48Hs2B_2MVAtQM3NNb2__p6c83SzEr_wKZms5k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290271398</pqid></control><display><type>article</type><title>Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><creator>Karlsson, Mikael C. ; Gonzalez, Santiago F. ; Welin, Josefin ; Fuxe, Jonas</creator><creatorcontrib>Karlsson, Mikael C. ; Gonzalez, Santiago F. ; Welin, Josefin ; Fuxe, Jonas</creatorcontrib><description>It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., ). Since then, metastatic spread of cancer cells to regional lymph nodes has been established as the most important prognostic factor in many types of cancer (Carter et al., ; Elston and Ellis, ). However, despite its clinical importance, lymph metastasis remains an underexplored area of tumor biology. Fundamental questions, such as when, how, and perhaps most importantly, why tumor cells disseminate through the lymphatic system, remain largely unanswered. Accordingly, no treatment strategies exist that specifically target lymph metastasis. The identification of epithelial‐mesenchymal transition (EMT) as a mechanism, which allows cancer cells to dedifferentiate and acquire enhanced migratory and invasive properties, has been a game changer in cancer research. Conceptually, EMT provides an explanation for why epithelial cancers with poor differentiation status are generally more aggressive and prone to metastasize than more differentiated cancers. Inflammatory cytokines, such as TGF‐β, which are produced and secreted by tumor‐infiltrating immune cells, are potent inducers of EMT. Thus, reactivation of EMT also links cancer‐related inflammation to invasive and metastatic disease. Recently, we found that breast cancer cells undergoing TGF‐β‐induced EMT acquire properties of immune cells allowing them to disseminate in a targeted fashion through the lymphatic system similar to activated dendritic cells during inflammation. Here, we review our current understanding of the mechanisms by which cancer cells spread through the lymphatic system and the links to inflammation and the immune system. We also emphasize how imaging techniques have the potential to further expand our knowledge of the mechanisms of lymph metastasis, and how lymph nodes serve as an interface between cancer and the immune system. This article presents a review on the role of EMT in cancer metastasis through the lymphatic system. The emphasis is on the role of TGF‐beta‐induced EMT as a link between cancer and inflammation, and how EMT cells acquire properties of immune cells.</description><identifier>ISSN: 1574-7891</identifier><identifier>ISSN: 1878-0261</identifier><identifier>EISSN: 1878-0261</identifier><identifier>DOI: 10.1002/1878-0261.12092</identifier><identifier>PMID: 28590032</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Animals ; Antigens ; B cells ; Breast cancer ; Cancer therapies ; Cell adhesion &amp; migration ; chemokines ; Cytokines ; Cytotoxicity ; Dendritic cells ; EMT ; Epithelial-Mesenchymal Transition - immunology ; Humans ; immune cell properties ; Immune system ; Inflammation ; Invasiveness ; Laboratories ; lymph metastasis ; Lymph nodes ; Lymph Nodes - immunology ; Lymph Nodes - pathology ; Lymphatic Metastasis ; Lymphatic system ; Medical prognosis ; Mesenchyme ; Metastases ; Metastasis ; Neoplasm Proteins - immunology ; Neoplasms - immunology ; Neoplasms - pathology ; Patients ; Prognosis ; Review ; Reviews ; Stem cells ; targeted migration ; TGF‐β ; Transforming Growth Factor beta - immunology ; Transforming growth factors ; Tumor cells ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Molecular oncology, 2017-07, Vol.11 (7), p.781-791</ispartof><rights>2017 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd.</rights><rights>COPYRIGHT 2017 John Wiley &amp; Sons, Inc.</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6392-411f0953a83dc68d61faf30145467829afe5fbd699dc5699143753a29b932e263</citedby><cites>FETCH-LOGICAL-c6392-411f0953a83dc68d61faf30145467829afe5fbd699dc5699143753a29b932e263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496496/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496496/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28590032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:136275534$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Karlsson, Mikael C.</creatorcontrib><creatorcontrib>Gonzalez, Santiago F.</creatorcontrib><creatorcontrib>Welin, Josefin</creatorcontrib><creatorcontrib>Fuxe, Jonas</creatorcontrib><title>Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system</title><title>Molecular oncology</title><addtitle>Mol Oncol</addtitle><description>It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., ). Since then, metastatic spread of cancer cells to regional lymph nodes has been established as the most important prognostic factor in many types of cancer (Carter et al., ; Elston and Ellis, ). However, despite its clinical importance, lymph metastasis remains an underexplored area of tumor biology. Fundamental questions, such as when, how, and perhaps most importantly, why tumor cells disseminate through the lymphatic system, remain largely unanswered. Accordingly, no treatment strategies exist that specifically target lymph metastasis. The identification of epithelial‐mesenchymal transition (EMT) as a mechanism, which allows cancer cells to dedifferentiate and acquire enhanced migratory and invasive properties, has been a game changer in cancer research. Conceptually, EMT provides an explanation for why epithelial cancers with poor differentiation status are generally more aggressive and prone to metastasize than more differentiated cancers. Inflammatory cytokines, such as TGF‐β, which are produced and secreted by tumor‐infiltrating immune cells, are potent inducers of EMT. Thus, reactivation of EMT also links cancer‐related inflammation to invasive and metastatic disease. Recently, we found that breast cancer cells undergoing TGF‐β‐induced EMT acquire properties of immune cells allowing them to disseminate in a targeted fashion through the lymphatic system similar to activated dendritic cells during inflammation. Here, we review our current understanding of the mechanisms by which cancer cells spread through the lymphatic system and the links to inflammation and the immune system. We also emphasize how imaging techniques have the potential to further expand our knowledge of the mechanisms of lymph metastasis, and how lymph nodes serve as an interface between cancer and the immune system. This article presents a review on the role of EMT in cancer metastasis through the lymphatic system. The emphasis is on the role of TGF‐beta‐induced EMT as a link between cancer and inflammation, and how EMT cells acquire properties of immune cells.</description><subject>Animals</subject><subject>Antigens</subject><subject>B cells</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cell adhesion &amp; migration</subject><subject>chemokines</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Dendritic cells</subject><subject>EMT</subject><subject>Epithelial-Mesenchymal Transition - immunology</subject><subject>Humans</subject><subject>immune cell properties</subject><subject>Immune system</subject><subject>Inflammation</subject><subject>Invasiveness</subject><subject>Laboratories</subject><subject>lymph metastasis</subject><subject>Lymph nodes</subject><subject>Lymph Nodes - immunology</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neoplasm Proteins - immunology</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Review</subject><subject>Reviews</subject><subject>Stem cells</subject><subject>targeted migration</subject><subject>TGF‐β</subject><subject>Transforming Growth Factor beta - immunology</subject><subject>Transforming growth factors</subject><subject>Tumor cells</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1574-7891</issn><issn>1878-0261</issn><issn>1878-0261</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>D8T</sourceid><recordid>eNqFks9u1DAQxiMEoqVw5oYiceGSrf8kTuaCVFUtIC3qhZ4trzPZuCT2EidUe-MReMY-CbNkWXURErIlj8a_-ewZfUnymrMFZ0yc86qsMiYUX3DBQDxJTg-ZpxQXZZ6VFfCT5EWMd4wVChQ8T05EVQBjUpwmt1cbN7bYOdM9_PjZY0Rv221vunQcjI9udMGnzqfWeItD2uNoIm0X07EdwrRu6cS02_ab1ozOpnEbR-xfJs8a00V8tT_Pktvrqy-XH7PlzYdPlxfLzCoJIss5bxgU0lSytqqqFW9MIxnPi1yVlQDTYNGsagVQW_o68FyWRAtYgRQolDxLslk33uNmWunN4HozbHUwTu9TXylCnYMSFRD_fubppsfaoqcuu6Oy4xvvWr0O33VBArRJ4N1eYAjfJoyj7l202HXGY5ii5sCAK6WqitC3f6F3YRo8jUMLAUyUXMIjam061M43gd61O1F9UUoOBVOFJGrxD4pWjb2zwWPjKH9UcD4X2CHEOGBz6JEzvXOO3vlE73yifzuHKt48Hs2B_2MVAtQM3NNb2__p6c83SzEr_wKZms5k</recordid><startdate>201707</startdate><enddate>201707</enddate><creator>Karlsson, Mikael C.</creator><creator>Gonzalez, Santiago F.</creator><creator>Welin, Josefin</creator><creator>Fuxe, Jonas</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>201707</creationdate><title>Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system</title><author>Karlsson, Mikael C. ; Gonzalez, Santiago F. ; Welin, Josefin ; Fuxe, Jonas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6392-411f0953a83dc68d61faf30145467829afe5fbd699dc5699143753a29b932e263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>B cells</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cell adhesion &amp; migration</topic><topic>chemokines</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Dendritic cells</topic><topic>EMT</topic><topic>Epithelial-Mesenchymal Transition - immunology</topic><topic>Humans</topic><topic>immune cell properties</topic><topic>Immune system</topic><topic>Inflammation</topic><topic>Invasiveness</topic><topic>Laboratories</topic><topic>lymph metastasis</topic><topic>Lymph nodes</topic><topic>Lymph Nodes - immunology</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neoplasm Proteins - immunology</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Review</topic><topic>Reviews</topic><topic>Stem cells</topic><topic>targeted migration</topic><topic>TGF‐β</topic><topic>Transforming Growth Factor beta - immunology</topic><topic>Transforming growth factors</topic><topic>Tumor cells</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karlsson, Mikael C.</creatorcontrib><creatorcontrib>Gonzalez, Santiago F.</creatorcontrib><creatorcontrib>Welin, Josefin</creatorcontrib><creatorcontrib>Fuxe, Jonas</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Molecular oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karlsson, Mikael C.</au><au>Gonzalez, Santiago F.</au><au>Welin, Josefin</au><au>Fuxe, Jonas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system</atitle><jtitle>Molecular oncology</jtitle><addtitle>Mol Oncol</addtitle><date>2017-07</date><risdate>2017</risdate><volume>11</volume><issue>7</issue><spage>781</spage><epage>791</epage><pages>781-791</pages><issn>1574-7891</issn><issn>1878-0261</issn><eissn>1878-0261</eissn><abstract>It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., ). Since then, metastatic spread of cancer cells to regional lymph nodes has been established as the most important prognostic factor in many types of cancer (Carter et al., ; Elston and Ellis, ). However, despite its clinical importance, lymph metastasis remains an underexplored area of tumor biology. Fundamental questions, such as when, how, and perhaps most importantly, why tumor cells disseminate through the lymphatic system, remain largely unanswered. Accordingly, no treatment strategies exist that specifically target lymph metastasis. The identification of epithelial‐mesenchymal transition (EMT) as a mechanism, which allows cancer cells to dedifferentiate and acquire enhanced migratory and invasive properties, has been a game changer in cancer research. Conceptually, EMT provides an explanation for why epithelial cancers with poor differentiation status are generally more aggressive and prone to metastasize than more differentiated cancers. Inflammatory cytokines, such as TGF‐β, which are produced and secreted by tumor‐infiltrating immune cells, are potent inducers of EMT. Thus, reactivation of EMT also links cancer‐related inflammation to invasive and metastatic disease. Recently, we found that breast cancer cells undergoing TGF‐β‐induced EMT acquire properties of immune cells allowing them to disseminate in a targeted fashion through the lymphatic system similar to activated dendritic cells during inflammation. Here, we review our current understanding of the mechanisms by which cancer cells spread through the lymphatic system and the links to inflammation and the immune system. We also emphasize how imaging techniques have the potential to further expand our knowledge of the mechanisms of lymph metastasis, and how lymph nodes serve as an interface between cancer and the immune system. This article presents a review on the role of EMT in cancer metastasis through the lymphatic system. The emphasis is on the role of TGF‐beta‐induced EMT as a link between cancer and inflammation, and how EMT cells acquire properties of immune cells.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>28590032</pmid><doi>10.1002/1878-0261.12092</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1574-7891
ispartof Molecular oncology, 2017-07, Vol.11 (7), p.781-791
issn 1574-7891
1878-0261
1878-0261
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_496289
source MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SWEPUB Freely available online
subjects Animals
Antigens
B cells
Breast cancer
Cancer therapies
Cell adhesion & migration
chemokines
Cytokines
Cytotoxicity
Dendritic cells
EMT
Epithelial-Mesenchymal Transition - immunology
Humans
immune cell properties
Immune system
Inflammation
Invasiveness
Laboratories
lymph metastasis
Lymph nodes
Lymph Nodes - immunology
Lymph Nodes - pathology
Lymphatic Metastasis
Lymphatic system
Medical prognosis
Mesenchyme
Metastases
Metastasis
Neoplasm Proteins - immunology
Neoplasms - immunology
Neoplasms - pathology
Patients
Prognosis
Review
Reviews
Stem cells
targeted migration
TGF‐β
Transforming Growth Factor beta - immunology
Transforming growth factors
Tumor cells
Tumors
Vascular endothelial growth factor
title Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T04%3A51%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epithelial%E2%80%90mesenchymal%20transition%20in%20cancer%20metastasis%20through%20the%20lymphatic%20system&rft.jtitle=Molecular%20oncology&rft.au=Karlsson,%20Mikael%20C.&rft.date=2017-07&rft.volume=11&rft.issue=7&rft.spage=781&rft.epage=791&rft.pages=781-791&rft.issn=1574-7891&rft.eissn=1878-0261&rft_id=info:doi/10.1002/1878-0261.12092&rft_dat=%3Cgale_swepu%3EA731950653%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2290271398&rft_id=info:pmid/28590032&rft_galeid=A731950653&rfr_iscdi=true